Highlight
- CHOEP/EPOCH regimens show improved 3-year overall survival compared to CHOP in lymphomatous adult T-cell leukemia/lymphoma (ATL).
- No significant survival benefit of CHOEP/EPOCH over CHOP was observed in acute ATL.
- Overall response rates between regimens were not statistically different across ATL subtypes.
- The study underscores the need for subtype-specific prospective clinical trials in aggressive ATL management.
